Generic Name and Formulations:
Gadodiamide 287mg/mL; soln for IV inj; preservative-free.
Indications for OMNISCAN:
For use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues. For use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space.
Adults and Children:
<2yrs: not established. Give as a bolus IV inj, followed by 5mL normal saline flush to ensure complete injection. ≥2yrs: CNS: 0.2mL/kg (0.1mmol/kg). Kidney: 0.1mL/kg (0.05mmol/kg). Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.2mL/kg (0.1mmol/kg).
Chronic, severe kidney disease (GFR <30mL/min/1.73m2). Acute kidney injury.
Not for intrathecal use. Nephrogenic systemic fibrosis (NSF).
Not for intrathecal use; may cause convulsions, coma, sensory and motor neurologic deficits. Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury (see Contraindications). Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and up to several hrs after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Renal impairment: use lowest effective dose. Avoid extravasation. Interpreting Omniscan MRI scans without a companion non-contrast MRI. Elderly. Pregnancy. Nursing mothers.
Gadolinium-based contrast agent.
Interferes with serum calcium measurements with some colorimetric methods.
Nausea, headache, dizziness; cardiac failure, arrhythmia, MI, hypersensitivity reactions.
Vials (5mL, 10mL, 15mL, 20mL)—10; Prefilled syringes (10mL, 15mL, 20mL)—10; Prefill Plus needle-free system (15mL, 20mL)—10 (prefilled syringe + sodium chloride 0.9% inj flush syringe)
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D